ERBB2 and neoplasm: Suppression of the PI3-K/Akt signaling cascade can be achieved by using pharmacologically active substances such as trastuzumab (anti-HER2 monoclonal antibody) or erlotinib (epidermal growth factor inhibitor) and, thus, prevent further tumor cell proliferation [10,11].